Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

被引：71
作者：
Jadvar, Hossein [1 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Div Nucl Med, Dept Radiol, 2250 Alcazar St,CSC Ste 102, Los Angeles, CA 90033 USA
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2017年 / 209卷 / 02期
基金：
美国国家卫生研究院;
关键词：
cancer; precision; radionuclide; therapy; RESISTANT PROSTATE-CANCER; COLORECTAL LIVER METASTASES; I-AND-T; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS; LU-177-PSMA-617 RADIOLIGAND THERAPY; BONE-SEEKING RADIOPHARMACEUTICALS; Y-90; RADIOEMBOLIZATION; HEPATOCELLULAR-CARCINOMA; MEMBRANE ANTIGEN; RADIATION-DOSIMETRY;
D O I：
10.2214/AJR.17.18264
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OBJECTIVE. This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field. CONCLUSION. TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.
引用
收藏
页码：277 / 288
页数：12
相关论文
共 168 条
[1]   The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].
Afshar-Oromieh, Ali ;
Hetzheim, Henrik ;
Kratochwil, Clemens ;
Benesova, Martina ;
Eder, Matthias ;
Neels, Oliver C. ;
Eisenhut, Michael ;
Kuebler, Wolfgang ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Mier, Walter ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705
[2]   68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept [J].
Ahmadzadehfar, Hojjat ;
Azgomi, Kambiz ;
Hauser, Stefan ;
Wei, Xiao ;
Yordanova, Anna ;
Gaertner, Florian C. ;
Kuerpig, Stefan ;
Strunk, Holger ;
Essler, Markus .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (03) :438-444
[3]   Assessing Intra-arterial Complications of Planning and Treatment Angiograms for Y-90 Radioembolization [J].
Ahmed, Osman ;
Patel, Mikin V. ;
Masrani, Abdulrahman ;
Chong, Bradford ;
Osman, Mohammed ;
Tasse, Jordan ;
Soni, Jayesh ;
Turba, Ulku Cenk ;
Arslan, Bulent .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (05) :704-711
[4]   Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis [J].
Al-Adra, D. P. ;
Gill, R. S. ;
Axford, S. J. ;
Shi, X. ;
Kneteman, N. ;
Liau, S. -S. .
EJSO, 2015, 41 (01) :120-127
[5]  
Allen Bj, 2013, J Biomed Phys Eng, V3, P67
[6]   Radiopeptide Imaging and Therapy in Europe [J].
Ambrosini, Valentina ;
Fani, Melpomeni ;
Fanti, Stefano ;
Forrer, Flavio ;
Maecke, Helmut R. .
JOURNAL OF NUCLEAR MEDICINE, 2011, 52 :42S-55S
[7]   Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223 [J].
Anderson, Peter M. ;
Subbiah, Vivek ;
Rohren, Eric .
CURRENT ADVANCES IN OSTEOSARCOMA, 2014, 804 :291-304
[8]  
[Anonymous], 2015, J CHEM-NY, DOI DOI 10.1155/2015/402746
[9]   Multimodality imaging following 90Y radioembolization:: A comprehensive review and pictorial essay [J].
Atassi, Bassel ;
Bangash, Affaan K. ;
Bahram, Ammar ;
Pizzi, Giuseppi ;
Lewandowski, Robert J. ;
Ryu, Robert K. ;
Sato, Kent T. ;
Gates, Vanessa L. ;
Mulcahy, Mary F. ;
Kulik, Laura ;
Miller, Frank ;
Yaghmai, Vahid ;
Murth, Ravi ;
Larson, Andrew ;
Omary, Reed A. ;
Salem, Riad .
RADIOGRAPHICS, 2008, 28 (01) :81-99
[10]   Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen [J].
Bander, NH ;
Nanus, DM ;
Milowsky, MI ;
Kostakoglu, L ;
Vallabahajosula, S ;
Goldsmith, SJ .
SEMINARS IN ONCOLOGY, 2003, 30 (05) :667-677
12345678910